LXRX compared with ENGN: revenue, margins and what each company keeps, and the suppliers and customers both name

LXRXLexicon Pharmaceuticals, Inc.

Mkt capRevenueRevenue

ENGNenGene Therapeutics Inc.

Mkt capRevenueRevenue

Compare

LXRXLexicon Pharmaceuticals, Inc.

ENGNenGene Therapeutics Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LXRX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±22.0%▼−3.67%×0.17

ENGN1 of 4 reports

Reportimpliedrealized× implied

Q3 FY26—▲+5.49%—

= impliedLXRX realized, solidENGN realized, hatchedOne scale, both sides: full bar = 22%× = |realized| ÷ impliedSource: market data

LXRXLexicon Pharmaceuticals, Inc.

1.42▼−4.05%· post 1.42

Mkt cap$631.8MRevenue$692,000Q2 FY26Revenue$144MFY25

ENGNenGene Therapeutics Inc.

1.50▼−1.86%· post 1.50

ClosedOct 30 '26

Mkt cap$102.5MRevenue—Revenue—

Compare

ClosedOct 30 '26

LXRXLexicon Pharmaceuticals, Inc.

ENGNenGene Therapeutics Inc.

1.42▼−4.05%post 1.42

Price

1.50▼−1.86%post 1.50

$631.8M

Mkt cap

$102.5M

Q2 FY26$692,000

Revenue

—

FY25$144M

Revenue

—

LXRX1.42▼−4.05%vsENGN1.50▼−1.86%ClosedOct 30 '26